For over 25 years, we have transformed the treatment landscape for pulmonary arterial hypertension (PAH).”
For over 25 years, we have transformed the treatment landscape for pulmonary arterial hypertension (PAH). We pioneered the first oral, inhaled and fixed dose combination therapies, resulting in a comprehensive portfolio that addresses three foundational PAH pathways. Building on our long-standing effort to transform PAH into a manageable condition, we are dedicated to improving patient outcomes to help patients live better lives every day.
We remain committed to revolutionizing the treatment paradigm, reaching patients earlier, removing hurdles to accessing best-in-class oral therapies, and pursuing innovations through research that can further advance the standard of care.
Our therapies have helped more than 400,000 patients globally. ”
J&J’s approach to pulmonary arterial hypertension
Our legacy is rooted in innovation and patient-centered care, delivering meaningful impact for the PAH community. We have continuously pushed boundaries and set industry benchmarks by focusing on patient needs. Our therapies have helped more than 400,000 patients globally and we have developed a robust body of evidence that provides essential insights into this rare disease. As a result, remarkably, we’ve seen the survival rate or PAH improve over time.
We have expansive real-world evidence programs that have generated valuable insights from long-term patient data, including two of the largest real-world registries (SPHERE, OPUS/OrPHeUS) and longest studies (SERAPHIN, GRIPHON) in PAH. In addition to our Phase 3 UNISUS trial, ongoing research helps us improve patient outcomes and guide future patient care with data-driven insights.
